Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.43 |
| ▸ | RAF1 | P04049 | 2/20 | 0.42 |
| ▸ | BRAF | P15056 | 2/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1018219 | 0.90 | ALB (0.49) | KDM4E | |
| SCHEMBL2620360 | 0.90 | SCN9A (0.46) | KDM4ESCN9ARXFP1MCHR1 | |
| SCHEMBL26035569 | 0.86 | CREBBP (0.47) | MAPK14RAF1BRAF | |
| SCHEMBL26035586 | 0.85 | RAF1 (0.54) | MAPK14RAF1BRAF | |
| SCHEMBL26035597 | 0.85 | MAPK14 (0.46) | MAPK14RAF1BRAF | |
| SCHEMBL26038393 | 0.84 | CSF1R (0.47) | MAPK14RAF1BRAF | |
| SCHEMBL26037325 | 0.84 | KDM4E (0.65) | KDM4ENPSR1RXFP1 | |
| SCHEMBL26035148 | 0.83 | SMO (0.47) | SCN9ARAF1BRAF | |
| SCHEMBL26035579 | 0.80 | NPC1 (0.55) | MAPK14 | |
| SCHEMBL26037249 | 0.78 | NPC1 (0.50) | MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265054-A1 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | GENENTECH, INC. (US) | 2023-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265054-A1 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | SHH, GLI1, SMO | KDM4E 411/4885MAPK14 698/4885NPSR1 1592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.